Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri

International Journal of Cancer

Volumn 101, Issue 6, 2002, Pages 526-531

  Beskow, Anna H ^a   Gyllensten, Ulf B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cervical cancer; HLA; HPV titer

Indexed keywords

ADULT; AGED; ALLELE; ANTIBODY TITER; ARTICLE; CHROMOSOMAL LOCALIZATION; EPITHELIUM CELL; FEMALE; GENE LOCATION; GENETIC REGULATION; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CARCINOMA IN SITU; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0037145316     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.90010     Document Type: Article

References (36)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst 1995;87:796-802.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ. Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [see comments]. J Pathol 1999;189:12-9.
4. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
5. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth- Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study [see comments]. Lancet 2000;355:2189-93.
6. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, Adami HO, Gyllensten UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8.
7. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 1999;73:4972-82.
8. Barnard P, Payne E, McMillan NA. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 2000;277:411-9.
9. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275:6764-9.
10. Hemmi H, Yoshino M, Yamazaki H, Naito M, Iyoda T, Omatsu Y, Shimoyama S, Letterio JJ, Nakabayashi T, Tagaya H, Yamane T, Ogawa M, et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta 1-dependent cells. Int Immunol 2001;13:695-704.
11. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542-9.
12. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-8.
13. Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000; 78:580-5.
14. Lee SJ, Cho YS, Cho MC, Shim JH, Lee KA, Ko KK, Choe YK, Park SN, Hoshino T, Kim S, Dinarello CA, Yoon DY. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001;67:497-504.
15. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-Cabello F, Garrido F, Stern PL. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000;55:401-11.
16. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61:237-42.
17. Eckert LO, Watts DH, Koutsky LA, Hawes SE, Stevens CE, Kuypers J, Kiviat NB. A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. Infect Dis Obstet Gynecol 1999;7:158-64.
18. Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ. HLA and susceptibility to cervical neoplasia. Hum Immunol 1999;60:337-42.
19. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3 [see comments]. Nature 1991; 352:723-5.
20. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-62.
21. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001;93:817-22.
22. Ylitalo N, Bergstrom T, Gyllensten U. Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. J Clin Microbiol 1995;33:1822-8.
23. Ylitalo N, Sorensen P, Josefsson A, Frisch M, Sparen P, Ponten J, Gyllensten U, Melbye M, Adami HO. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer 1999;81:357-65.
24. Josefsson A, Livak K, Gyllensten U. Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay. J Clin Microbiol 1999;37:490-6.
25. Bugawan TL, Erlich HA. Rapid typing of HLA-DQB1 DNA polymorphism using nonradioactive oligonucleotide probes and amplified DNA. Immunogenetics 1991;33:163-70.
26. Scharf SJ, Griffith RL, Erlich HA. Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive oligonucleotide probes. Hum Immunol 1991;30:190-201.
27. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
28. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000;182:595-8.
29. Odunsi K, Ganesan T. Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. Int J Mol Med 2001;8:405-12.
30. Hu X, Guo Z, Tianyun P, Ponten F, Wilander E, Andersson S, Ponten J. HPV typing and HPV16 E6-sequence variations in synchronous lesions of cervical squamous-cell carcinoma from Swedish patients. Int J Cancer 1999;83:34-7.
31. Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM, Holmes KK, Kiviat NB. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:796-802.
32. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 2001;94:711-6.
33. Mann DL, Garner RP, Dayhoff DE, Cao K, Fernandez-Vina MA, Davis C, Aronson N, Ruiz N, Birx DL, Michael NL. Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans. J Infect Dis 1998; 178:1799-802.
34. Saah AJ, Hoover DR, Weng S, Carrington M, Mellors J, Rinaldo CR, Mann D, Apple R, Phair JP, Detels R, O'Brien S, Enger C, et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. Aids 1998;12:2107-13.
35. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
36. Ghaderi M, Nikitina Zake L, Wallin K, Wiklund F, Hallmans G, Lenner P, Dillner J, Sanjeevi CB. Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. Hum Immunol 2001;62:1153-8.